Active Ingredient History
Sorafenib (BAY 43-9006), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer, hepatocellular carcinoma and for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment. It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib was shown to interact with multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT- 3, VEGFR- 2, VEGFR- 3, and PDGFR- ß). Several of these kinases are thought to be involved in angiogenesis. Thus, sorafenib may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and Kit signaling) and/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling). Sorafenib inhibited tumor growth of the murine renal cell carcinoma, RENCA, and several other human tumor xenografts in athymic mice. A reduction in tumor angiogenesis was seen in some tumor xenograft models. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Adenocarcinoma, Follicular (approved 2005)
Carcinoma, Hepatocellular (approved 2005)
Carcinoma, Renal Cell (approved 2005)
Adenocarcinoma (Phase 3)
Adenoma, Liver Cell (Phase 1/Phase 2)
Adrenocortical Carcinoma (Phase 2)
Anemia (Phase 1)
Antineoplastic Agents (Phase 2)
Astrocytoma (Phase 1)
Bile Duct Neoplasms (Phase 2)
Biliary Tract Neoplasms (Phase 1/Phase 2)
Biological Availability (Phase 1)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 3)
Breast Neoplasms, Male (Phase 2)
Burkitt Lymphoma (Phase 1)
Carcinoid Tumor (Phase 1)
Carcinoma (Phase 3)
Carcinoma, Hepatocellular (Phase 4)
Carcinoma, Islet Cell (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 4)
Carcinoma, Small Cell (Phase 1)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 1)
Carcinoma, Verrucous (Phase 2)
Chemoembolization, Therapeutic (Phase 3)
Cholangiocarcinoma (Phase 1/Phase 2)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Desmoplastic Small Round Cell Tumor (Phase 2)
Digestive System Diseases (Phase 3)
Digestive System Neoplasms (Phase 3)
Drug Interactions (Phase 2)
Drugs, Investigational (Phase 3)
Esophageal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Fasting (Phase 1)
Fibrosarcoma (Phase 2)
Fibrosis (Phase 1)
Gallbladder Neoplasms (Phase 2)
Gastrinoma (Phase 2)
Gastrointestinal Stromal Tumors (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 2)
Glucagonoma (Phase 2)
Graft vs Host Disease (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Hematopoietic Stem Cell Transplantation (Phase 4)
Hepatectomy (Phase 4)
Hepatitis B (Phase 2)
Hepatitis C (Phase 2)
Hepatitis C, Chronic (Phase 1)
Hepatoblastoma (Phase 3)
Hepatopulmonary Syndrome (Phase 2)
Herpesvirus 8, Human (Phase 1)
Hodgkin Disease (Phase 1)
Hypertension, Portal (Phase 2)
Insulinoma (Phase 2)
Intestinal Neoplasms (Phase 2)
Keloid (Phase 2)
Kidney Diseases (Phase 2)
Kidney Neoplasms (Phase 3)
Klatskin Tumor (Phase 2)
Leiomyosarcoma (Phase 2)
Leukemia (Phase 3)
Leukemia, Biphenotypic, Acute (Phase 1/Phase 2)
Leukemia, Eosinophilic, Acute (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Monocytic, Acute (Phase 2/Phase 3)
Leukemia, Myeloid (Phase 3)
Leukemia, Myeloid, Acute (Phase 4)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Myelomonocytic, Acute (Phase 1)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Leukemia, Myelomonocytic, Juvenile (Phase 1)
Leukemia, Promyelocytic, Acute (Phase 1)
Liver Cirrhosis (Phase 2)
Liver Diseases (Phase 3)
Liver Neoplasms (Phase 4)
Liver Neoplasms, Experimental (Phase 1/Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 1/Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 1)
Lymphoma, Follicular (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 1)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 2)
Lymphomatoid Granulomatosis (Phase 1)
Melanoma (Phase 3)
Mesothelioma (Phase 2)
Multiple Endocrine Neoplasia Type 2a (Phase 2)
Multiple Endocrine Neoplasia Type 2b (Phase 2)
Multiple Myeloma (Phase 2)
Mutation (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 1/Phase 2)
Nasopharyngeal Neoplasms (Phase 2)
Neoplasm Metastasis (Phase 4)
Neoplasms (Phase 4)
Neoplasms by Histologic Type (Phase 3)
Neoplasms by Site (Phase 3)
Neoplasms, Glandular and Epithelial (Phase 3)
Neoplasms, Squamous Cell (Phase 1/Phase 2)
Neuroblastoma (Phase 1)
Neuroendocrine Tumors (Phase 2)
Neurofibroma (Phase 2)
Neurofibroma, Plexiform (Phase 1)
Neurofibromatosis 1 (Phase 1)
Neurofibrosarcoma (Phase 2)
Oligodendroglioma (Phase 1)
Osteosarcoma (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 3)
Pediatrics (Phase 2)
Pharmacokinetics (Phase 1)
Primary Myelofibrosis (Phase 1)
Prostatic Neoplasms (Phase 2)
Protein Kinase Inhibitors (Phase 2)
Pulmonary Arterial Hypertension (Phase 1)
Quality of Life (Phase 2/Phase 3)
Radiotherapy (Phase 3)
Rectal Neoplasms (Phase 1)
Recurrence (Phase 3)
Rhabdomyosarcoma (Phase 2)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 2)
Sarcoma, Kaposi (Phase 1)
Sarcoma, Myeloid (Phase 3)
Sarcoma, Synovial (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Somatostatinoma (Phase 2)
Sorafenib (Phase 4)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 2)
Testicular Neoplasms (Phase 2)
Thrombosis (Phase 3)
Thyroid Cancer, Papillary (Phase 2)
Thyroid Carcinoma, Anaplastic (Phase 2)
Thyroid Neoplasms (Phase 3)
Tongue Neoplasms (Phase 2)
Ureteral Neoplasms (Phase 1)
Urethral Neoplasms (Phase 2)
Urinary Bladder (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 1/Phase 2)
Uterine Neoplasms (Phase 2)
Vipoma (Phase 2)
Waldenstrom Macroglobulinemia (Phase 1)
Wilms Tumor (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue